Extended Data Fig. 4: Recurrence-free survival by receptor status and DTC status in the CLEVER trial.
From: Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial
a, Recurrence-free survival by receptor status. To avoid overlapping RFS curves, a small amount of vertical spacing has been added to the lines at 100% RFS to distinguish between the different receptor groups. b, Recurrence-free survival by DTC detection status ascertained after cycle 6 of treatment. Number of patients at risk at each time point is shown.
